ChromaDex®'s Founder, Frank Jaksch, Appears as an Industry Expert on "Dateline NBC"
Episode Explores Dietary Supplement Industry's Diligence in Analytical Testing
IRVINE, Calif., March 19, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company providing proprietary, science-based solutions and ingredients to the dietary supplement industry, was featured as an industry expert on supplement testing on the investigative reporting television series "Dateline NBC," which aired Sunday, March 18th at 7 p.m. EDT on NBC. The show focused on the practice of fraudulent analytical testing practices known as "dry labbing," in which lab results pertaining to the potency and identity of ingredients as labeled are suspected of having been deliberately manipulated or fabricated.
"There are challenges in the dietary supplement industry in that laboratories supplying fictional results in lieu of performing appropriate analytical tests may mislead their clients and the public. This is a practice known as 'dry labbing,' " said ChromaDex Founder Frank Jaksch. "The 'Dateline NBC' investigative segment was an important first step in addressing this problem. Consumers need to have confidence that what is on the label matches what is in the product."
ChromaDex was established in 1999 in response to growing demand for natural product reference standards, materials and services. ChromaDex is an innovative natural products company providing proprietary, science-based solutions and ingredients to the dietary supplement, food, beverage, cosmetics and pharmaceutical industries. Today, ChromaDex continues its leadership in the reference standards and services business with a customer-centric approach supported by scientific rigor. Clients include government, academia and leading Fortune 500 Companies. Its expertise in this market gives it a unique foundation for combining the power of nature with the science of health to develop and market natural and novel ingredients. For more information visit www.chromadex.com.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
ChromaDex Investor Contact:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Frank Jaksch, Founder and CSO
SOURCE ChromaDex Corporation
More by this Source
ChromaDex® Updates Research Activity Agreements For Its NIAGEN™ Nicotinamide Riboside
Nov 22, 2013, 08:30 ET
ChromaDex® Reports Results for the Third Quarter 2013
Nov 21, 2013, 17:50 ET
ChromaDex® Reports Results for the Second Quarter 2013
Aug 13, 2013, 08:20 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.